HeartBeam announces initiation of VALID-ECG study for cardiac monitoring

HeartBeam announced that it has enrolled the first patients in the VALID-ECG or Clinical Validation of the AIMIGo 12-Lead ECG Synthesis Software for Arrhythmia Detection, pivotal study. The first patients were enrolled at Atlanta Heart Specialists, a top cardiology physician practice in Atlanta, GA. The VALID-ECG study will evaluate the performance of a 12-lead ECG synthesized from its credit card-sized HeartBeam AIMIGo system compared to that of a standard hospital-based 12-lead ECG using both quantitative and qualitative methodologies for assessment of arrhythmias. HeartBeam AIMIGo leverages HeartBeam’s proprietary 3D vector electrocardiography or 3D VECG, technology to capture signals in three projections and synthesize a 12-lead ECG. “We are thrilled to be part of this important study as AIMIGo represents a significant leap in cardiac monitoring technology. It brings the power of 3D VECG into a familiar 12-lead ECG waveform which is used to evaluate a range of cardiac conditions on a daily basis,” said David D. Suh, MD, FACC, Director of Research at Atlanta Heart Specialists. “The attractive, small form factor of AIMIGo makes it easy for patients to use the device whenever necessary. In addition, the clinical implications of 3D VECG technology could be potentially broad-ranging and extend to a variety of applications.” .